目的 探討不同分子分型乳腺浸潤性導(dǎo)管癌手術(shù)病例標(biāo)本中P53、表皮生長因子受體（EGFR）和Ki-67的表達(dá)及臨床意義。 方法 采用免疫組織化學(xué)鏈霉菌抗生物素蛋白-過氧化物酶連接法法對2010年1月－2011年7月446例乳腺浸潤性導(dǎo)管癌患者標(biāo)本進(jìn)行分子分型，并同時檢測其P53、EGFR、Ki-67等的表達(dá)。 結(jié)果 P53和Ki-67在人類表皮生長因子受體2（HER2）過表達(dá)型、基底細(xì)胞樣型、未分類型中的表達(dá)明顯強(qiáng)于管腔A型及管腔B型（P＜0.05）；HER2過表達(dá)型和未分類型中的EGFR表達(dá)明顯強(qiáng)于管腔A型及管腔B型（P＜0.05）。 結(jié)論 在使用雌激素受體、c-erbB-2等指標(biāo)對浸潤性導(dǎo)管癌進(jìn)行分子分型時同時檢測P53、EGFR及Ki-67等標(biāo)記物，有助于更加精準(zhǔn)的評估腫瘤的生物學(xué)行為及預(yù)后 ，對靶向藥物的個體化治療提供參考和療效預(yù)測有重要意義。
引用本文： 王雷,宋林紅,朱鴻,付靜,李科. 不同分子分型乳腺浸潤性導(dǎo)管癌中的P53、表皮生長因子受體及Ki-67的表達(dá)及意義. 華西醫(yī)學(xué), 2012, 27(9): 1349-1353. doi: 復(fù)制
| 1. | Elston CW, Ellis IO. Classification of malignant breast disease[M]// Elston CW, Ellis IO. The breast. Systemic pathology. 3rd ed. Edinburgh: Churchill Livingstone, 1998: 239-247. |
| 2. | 唐平, 魏兵, Hicks DG, 等. 乳腺癌的分子分類及其臨床應(yīng)用[J]. 中華病理學(xué)雜志, 2009, 38(1): 13-17. |
| 3. | Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study[J]. Am J Epidemiol, 2009, 169(10): 1251-1259. |
| 4. | Demonty G, Bernard-Marty C, Puglisi F, et al. Progress and new standards of care in the management of HER-2 positive breast cancer[J]. Eur J Cancer, 2007, 43(3): 497-509. |
| 5. | 林敏, 陳忠清, 包蕓, 等. 乳腺浸潤性導(dǎo)管癌分子亞型與臨床病理特征及預(yù)后的關(guān)系[J]. 中華病理雜志, 2010, 39(6): 372-376. |
| 6. | 袁中玉, 王樹森, 朱美琴, 等. 不同分子亞型乳腺癌的臨床特征和預(yù)后[J]. 中華腫瘤雜志, 2008, 30(6): 456-461. |
| 7. | Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J]. Breast Cancer Res, 2006, 8(4): R34. |
| 8. | Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-alpha by P53 in human breast cancer cells[J]. Cancer Res, 2009, 69(16): 3405-3414. |
| 9. | Mao XY, Fan CF, Zheng HC, et al. P53 nuclear accumulation and ER alpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women [J]. J Exp Clin Cancer Res, 2010, 29(8): 112. |
| 10. | 曾敏. survivin 在乳腺癌中的表達(dá)及其與P53基因的關(guān)系[J]. 中華實(shí)用診斷與治療雜志, 2009, 23(12): 1181-1183. |
| 11. | Yuen PM, Ng PS, Leung PL, et al. Outcome in laparoscopic management of persistent adnexal mass during the second trimester of the second trimester of pregnancy[J]. Surg Endosc, 2004, 18(9): 1354-1357. |
| 12. | Hanprasertpong J, Tungsinmunkong K, Chichareon S, et al. Correlation of P53 and Ki-67 (MIB-1) expressions with clinicopathological feat ures and prognos is of early stage cervical squamous cell carcinomas[J]. J Obstet Gynaecol Res, 2010, 36(3): 572-580. |
| 13. | Tzaida O, Gogas H, Dafni U, et al. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy[J]. Oncology, 2007, 72(5-6): 388-396. |
| 14. | Wu M, Jung L, Zhou J, et al. Dissecting genetic requirements of human breast tumorigenes is in a tissue transgenic model of human breast cancer in mice[J]. Proc Natl Acad Sci USA, 2009, 106(17): 7022-7077. |
| 15. | Zhang Y, Opresko L, Shankaran H, et al. HER/ErbB receptorin teractions and signaling patterns in human mammary epithelialcells[J]. BMC Cell Biol, 2009, 10: 78-80. |
- 1. Elston CW, Ellis IO. Classification of malignant breast disease[M]// Elston CW, Ellis IO. The breast. Systemic pathology. 3rd ed. Edinburgh: Churchill Livingstone, 1998: 239-247.
- 2. 唐平, 魏兵, Hicks DG, 等. 乳腺癌的分子分類及其臨床應(yīng)用[J]. 中華病理學(xué)雜志, 2009, 38(1): 13-17.
- 3. Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study[J]. Am J Epidemiol, 2009, 169(10): 1251-1259.
- 4. Demonty G, Bernard-Marty C, Puglisi F, et al. Progress and new standards of care in the management of HER-2 positive breast cancer[J]. Eur J Cancer, 2007, 43(3): 497-509.
- 5. 林敏, 陳忠清, 包蕓, 等. 乳腺浸潤性導(dǎo)管癌分子亞型與臨床病理特征及預(yù)后的關(guān)系[J]. 中華病理雜志, 2010, 39(6): 372-376.
- 6. 袁中玉, 王樹森, 朱美琴, 等. 不同分子亞型乳腺癌的臨床特征和預(yù)后[J]. 中華腫瘤雜志, 2008, 30(6): 456-461.
- 7. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J]. Breast Cancer Res, 2006, 8(4): R34.
- 8. Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-alpha by P53 in human breast cancer cells[J]. Cancer Res, 2009, 69(16): 3405-3414.
- 9. Mao XY, Fan CF, Zheng HC, et al. P53 nuclear accumulation and ER alpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women [J]. J Exp Clin Cancer Res, 2010, 29(8): 112.
- 10. 曾敏. survivin 在乳腺癌中的表達(dá)及其與P53基因的關(guān)系[J]. 中華實(shí)用診斷與治療雜志, 2009, 23(12): 1181-1183.
- 11. Yuen PM, Ng PS, Leung PL, et al. Outcome in laparoscopic management of persistent adnexal mass during the second trimester of the second trimester of pregnancy[J]. Surg Endosc, 2004, 18(9): 1354-1357.
- 12. Hanprasertpong J, Tungsinmunkong K, Chichareon S, et al. Correlation of P53 and Ki-67 (MIB-1) expressions with clinicopathological feat ures and prognos is of early stage cervical squamous cell carcinomas[J]. J Obstet Gynaecol Res, 2010, 36(3): 572-580.
- 13. Tzaida O, Gogas H, Dafni U, et al. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy[J]. Oncology, 2007, 72(5-6): 388-396.
- 14. Wu M, Jung L, Zhou J, et al. Dissecting genetic requirements of human breast tumorigenes is in a tissue transgenic model of human breast cancer in mice[J]. Proc Natl Acad Sci USA, 2009, 106(17): 7022-7077.
- 15. Zhang Y, Opresko L, Shankaran H, et al. HER/ErbB receptorin teractions and signaling patterns in human mammary epithelialcells[J]. BMC Cell Biol, 2009, 10: 78-80.